Abdulla F A, Smith P A
Department of Physical Therapy, Tennessee State University, Nashville, Tennessee 37290, USA.
J Neurosci. 1998 Dec 1;18(23):9685-94. doi: 10.1523/JNEUROSCI.18-23-09685.1998.
There is some doubt as to the effectiveness of opioids in the management of neuropathic pain. We therefore examined the actions of morphine and the opioid-like peptide nociceptin (both 1 mu) on dorsal root ganglion (DRG) neurons that were isolated from control or from nerve-injured rats. Both substances reduced omega-conotoxin (CTX) GVIA-sensitive, N-type Ca2+ channel current and small persistent nifedipine/ CTX-insensitive (non-N, non-L type) current. Nifedipine-sensitive L-type current was unaffected. The effect of nociceptin was antagonized by naloxone benzoylhydrazone (nalbzoh) but not by naloxone. Sciatic nerve section (axotomy) profoundly reduced the effects of morphine and the mu-receptor agonist D-ala2, N-Me-Phe4,Gly-ol5 enkephalin (DAMGO). The effect of the kappa-agonist [(+)-(5alpha,7alpha, 8beta)-N-methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(4, 5)dec-8-yl)-benzeneacetamide] (U69593) was unchanged, whereas the effect of nociceptin was increased. All agonists produced their strongest effects on the small, putative nociceptive cells and their weakest effects on the largest cells. The delta-receptor agonist, enkephalin D-pen2,5 (DPDPE), was without effect on control or on axotomized cells. These and other data suggest that the functional downregulation of mu-opioid receptors on sensory nerves contributes to the poor efficacy of opioids in neuropathic pain. Also, the increased effectiveness of nociceptin after axotomy supports the hypothesis that its actions are mediated via a "non-opioid" receptor. Pronounced suppression of Ca2+ channel current in axotomized DRG neurons by nociceptin led to a reduction in Ca2+-dependent K+ conductance and a marked increase in excitability. Despite this, the spinal administration of nociceptin or agonists that activate ORL1 (opioid-like orphan receptor) may prove to be of clinical interest in the management of neuropathic pain.
阿片类药物在治疗神经性疼痛方面的有效性存在一定疑问。因此,我们研究了吗啡和类阿片肽痛敏肽(均为1 μM)对从对照大鼠或神经损伤大鼠分离出的背根神经节(DRG)神经元的作用。两种物质均降低了ω-芋螺毒素(CTX)GVIA敏感的N型Ca2+通道电流以及小的持续性硝苯地平/CTX不敏感(非N型、非L型)电流。硝苯地平敏感的L型电流未受影响。纳洛酮苯甲酰腙(nalbzoh)可拮抗痛敏肽的作用,但纳洛酮无此作用。坐骨神经切断术(轴突切断)显著降低了吗啡和μ受体激动剂D-ala2,N-Me-Phe4,Gly-ol5脑啡肽(DAMGO)的作用。κ激动剂[(+)-(5α,7α, 8β)-N-甲基-N-(7-(1-吡咯烷基)-1-氧杂螺(4, 5)癸-8-基)-苯乙酰胺](U69593)的作用未改变,而痛敏肽的作用增强。所有激动剂对小的、假定的伤害性感受细胞产生最强作用,对最大的细胞产生最弱作用。δ受体激动剂脑啡肽D-pen2,5(DPDPE)对对照细胞或轴突切断的细胞均无作用。这些及其他数据表明,感觉神经上μ阿片受体的功能下调导致阿片类药物在神经性疼痛中疗效不佳。此外,轴突切断后痛敏肽有效性的增加支持了其作用通过“非阿片”受体介导的假说。痛敏肽对轴突切断的DRG神经元中Ca2+通道电流的显著抑制导致Ca2+依赖性K+电导降低以及兴奋性显著增加。尽管如此,脊髓给予痛敏肽或激活ORL1(类阿片孤儿受体)的激动剂在治疗神经性疼痛方面可能具有临床意义。